JE Cleantech Holdings Limited (NASDAQ:JCSE) Short Interest Down 61.7% in April

JE Cleantech Holdings Limited (NASDAQ:JCSE) saw a large decline in short interest in the month of April. As of April 30th, there was short interest totaling 21,125 shares, a decline of 61.7% from the April 15th total of 55,101 shares. Based on an average trading volume of 69,120 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.1% of the company’s shares are sold short.

JE Cleantech Price Performance

Shares of JCSE traded down $0.03 during midday trading on Friday, reaching $1.24. 26,163 shares of the stock were exchanged, compared to its average volume of 59,732. JE Cleantech has a 52 week low of $0.77 and a 52 week high of $2.50. The company’s 50 day moving average is $1.18 and its two-hundred day moving average is $1.23.

JE Cleantech (NASDAQ:JCSE) last posted its quarterly earnings results on Friday, May 8th. The company reported $0.30 earnings per share (EPS) for the quarter. The firm had revenue of $5.33 million for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d)” rating on shares of JE Cleantech in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, JE Cleantech has an average rating of “Sell”.

JE Cleantech Company Profile

JE Cleantech Holdings Ltd. is an Israel-based environmental technology firm specializing in advanced water and wastewater treatment solutions. The company designs, manufactures and markets a suite of modular treatment systems that integrate proprietary membrane filtration, advanced oxidation processes, biological treatment and customized chemical formulations. Its offerings address water purification, recycling and process water challenges across municipal, industrial and agricultural end markets.

Through a combination of standardized equipment platforms and bespoke engineering services, JE Cleantech helps clients meet stringent regulatory requirements, reduce freshwater intake and lower overall treatment costs.